Biotech Archives - Page 703 of 733

1 minute read

Rain Therapeutics Concludes Enrolment In Late-Stage Tissue Cancer Study, Expects Topline Data In H1 2023

August 4, 12:37 PM

Rain Therapeutics (NASDAQ: RAIN) has completed patient enrolment in its Phase 3 MANTRA trial of its lead asset, milademetan for well-differentiated / dedifferentiated (WD/DD) liposarcoma (LPS).

RAIN

1 minute read

Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings

By Vandana Singh

August 4, 12:18 PM

Organon & Co’s (NYSE:OGN) Q2 sales decreased 1% Y/Y to $1.59 billion, beating the consensus of $1.54 billion. The sales…

OGN

2 minute read

ChemoCentryx Shares Are Jumping 110% Thursday: Here’s Why

By Dylan Wechsler

August 4, 12:18 PM

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

AMGN

1 minute read

Gilead Sciences Bets $400M On Inflammatory Diseases Focused UK Based Firm

By Vandana Singh

August 4, 12:13 PM

Gilead Sciences Inc (NASDAQ:GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists…

GILD

2 minute read

FDA Lifts Clinical Hold On BioCryst’s BCX9930 Program For Rare Blood Disorder

By Vandana Singh

August 4, 12:11 PM

The FDA lifted a partial clinical hold on BioCryst Pharmaceuticals Inc’s (NASDAQ:BCRX) BCX9930 program. The company will resume enrollment under revised protocols…

BCRX

1 minute read

Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end

By Ragothaman Srinivasan

August 4, 12:03 PM

Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing once every three months or longer.

ATXS

1 minute read

BioCryst Pharmaceuticals Says FDA Has Lifted Partial Clinical Hold On BCX9930 Program

By Bill Haddad

August 4, 7:58 AM

On August 4, 2022, the company announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under

BCRX

1 minute read

FDA Says Travere’s Sparsentan Data Not Sufficient For Accelerated Approval In One Indication

By Vandana Singh

August 4, 7:36 AM

Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare disease affecting the kidney filters.

TVTX